For example, while resistance to proto‐oncogene B‐Raf (BRAF) inhibitors usually evolves in melanomas after only a few months of treatment, immunotherapy with checkpoint inhibitors, such as nivolumab and ipilimumab, is able to slow down the growth of these tumours, to induce durable immune responses and prolong survival (Larkin et al., 2019). The gene discussed is BRAF; the disease is melanoma.